BTIG Reiterates Buy Rating on SOPH, Sets $8 Price Target
BTIG analyst Mark Massaro reaffirms a positive outlook on SOPH, a 63.93% upside from the current price.
Key Points
- BTIG analyst Mark Massaro reiterated a Buy rating on SOPH with a target price of $8 on June 15, 2026.
- BTIG's $8 price target implies 63.93% upside from SOPHiA GENETICS SA's ($SOPH) current $4.88 share price.
- SOPH shares are currently trading around $4.88, reflecting the analyst's confidence despite the stock's lower price.
- The reaffirmation by BTIG comes amid insider transactions and other institutional activities in SOPH's stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG's analyst Mark Massaro has reiterated a Buy rating for SOPH, setting a price target of $8. This update was made on June 15, 2026, as the stock currently trades around $4.88. Massaro's reaffirmation reflects continued confidence in SOPH's potential upside.
Other Institutional Activity in SOPH
Several institutional investors have shown interest in SOPH. Generation Investment Management LLP holds 6,789,560 shares valued at approximately $33.6 million, while Akre Capital Management LLC owns 3,719,140 shares worth about $18.4 million. Banque Pictet & Cie SA holds 2,208,280 shares valued at roughly $10.9 million. Soleus Capital Management, L.P. significantly increased its stake by adding 1,850,000 shares, bringing its total to 1,850,000 shares valued at about $9.2 million. Royce & Associates LP also boosted its holdings, adding 1,386,055 shares to reach 1,816,312 shares, valued at approximately $9 million.
SOPHiA GENETICS SA Stock Down 40.0%
Shares of SOPH are trading near $4.88. The stock has seen various insider activities and institutional interests, indicating a dynamic market environment.
$SOPH price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at SOPHiA GENETICS SA
There have been notable insider transactions at SOPH. On June 10, 2026, CEO Jurgi Camblong sold 8,500 shares at $5.24 each, under a planned sale. Earlier, on June 5, 2026, CFO George Cardoza purchased 20,000 shares at $4.95 apiece. Chief Medical Officer Philippe Menu sold 5,000 shares on May 26, 2026, at $4.95 each, also as part of a planned sale.
Analysts Set New Price Targets
On June 15, 2026, BTIG reiterated its Buy rating for SOPH, setting a price target of $8. Previously, the firm maintained the same rating and target on April 15, 2026. Other analysts like Guggenheim have also maintained a Buy rating with a target of $7 back in January 2026.
Bottom Line
BTIG's reaffirmation of SOPH with a Buy rating and an $8 target highlights continued confidence in the company's future prospects. The stock's current trading price of $4.88 suggests potential upside, as reflected by both institutional activity and insider transactions. Investors will watch for further developments as SOPH continues to attract attention from analysts and major funds.
Get SOPHiA GENETICS SA alerts
New 13F filings, insider trades, and analyst moves on $SOPH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.